ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.

Oncologist · 2022 · PMC8842297 · PMID 35305096

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

We found ALKi treatment at this point to be associated with a nonsignificant trend for better OS compared with chemotherapy.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.